array(40) {
  [0]=>
  string(4) "3134"
  ["article_id"]=>
  string(4) "3134"
  [1]=>
  string(76) "Switching to smart charging electric vehicles could save the UK over £1bn"
  ["article_title"]=>
  string(76) "Switching to smart charging electric vehicles could save the UK over £1bn"
  [2]=>
  string(150) "Introducing smart charging infrastructure for electric vehicles could reduce the need to build extra storage into the National Grid – saving the"
  ["short_description"]=>
  string(150) "Introducing smart charging infrastructure for electric vehicles could reduce the need to build extra storage into the National Grid – saving the"
  [3]=>
  string(576) "
Introducing smart charging infrastructure for electric vehicles could reduce the need to build extra storage into the National Grid – saving the UK power network £1.16bn a year, 
&#nl
The post Switching to smart charging electric vehicles could save the UK over £1bn appeared first on Compelo -  latest news, features and insight on influencers and innovators within business.
&#nl"
  ["description"]=>
  string(576) "
Introducing smart charging infrastructure for electric vehicles could reduce the need to build extra storage into the National Grid – saving the UK power network £1.16bn a year, 
&#nl
The post Switching to smart charging electric vehicles could save the UK over £1bn appeared first on Compelo -  latest news, features and insight on influencers and innovators within business.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "96"
  ["rss_id"]=>
  string(2) "96"
  [14]=>
  string(57) "https://www.compelo.com/smart-charging-electric-vehicles/"
  ["blog_url"]=>
  string(57) "https://www.compelo.com/smart-charging-electric-vehicles/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:58:31"
  ["create_at"]=>
  string(19) "2019-06-09 21:58:31"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3332"
  ["article_id"]=>
  string(4) "3332"
  [1]=>
  string(103) "Sensorion receives EMA agreement on the pediatric investigation plan for Arazasetron in two indications"
  ["article_title"]=>
  string(103) "Sensorion receives EMA agreement on the pediatric investigation plan for Arazasetron in two indications"
  [2]=>
  string(154) "“We are delighted by this outcome which we regard as an important stage for Sensorion and young patients. Indeed, this approval will allow Sensorion"
  ["short_description"]=>
  string(154) "“We are delighted by this outcome which we regard as an important stage for Sensorion and young patients. Indeed, this approval will allow Sensorion"
  [3]=>
  string(657) "
“We are delighted by this outcome which we regard as an important stage for Sensorion and young patients. Indeed, this approval will allow Sensorion to develop SENS-401 for 
&#nl
The post Sensorion receives EMA agreement on the pediatric investigation plan for Arazasetron in two indications appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(657) "
“We are delighted by this outcome which we regard as an important stage for Sensorion and young patients. Indeed, this approval will allow Sensorion to develop SENS-401 for 
&#nl
The post Sensorion receives EMA agreement on the pediatric investigation plan for Arazasetron in two indications appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(156) "https://www.pharmaceutical-business-review.com/news/sensorion-receives-ema-agreement-on-the-pediatric-investigation-plan-for-arazasetron-in-two-indications/"
  ["blog_url"]=>
  string(156) "https://www.pharmaceutical-business-review.com/news/sensorion-receives-ema-agreement-on-the-pediatric-investigation-plan-for-arazasetron-in-two-indications/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3333"
  ["article_id"]=>
  string(4) "3333"
  [1]=>
  string(89) "CHMP recommends EU approval of Roche’s Tecentriq plus Abraxane for metastatic TNBC"
  ["article_title"]=>
  string(89) "CHMP recommends EU approval of Roche’s Tecentriq plus Abraxane for metastatic TNBC"
  [2]=>
  string(154) "“This CHMP recommendation marks a breakthrough in the treatment of triple-negative breast cancer, an aggressive type of breast cancer with high unme"
  ["short_description"]=>
  string(154) "“This CHMP recommendation marks a breakthrough in the treatment of triple-negative breast cancer, an aggressive type of breast cancer with high unme"
  [3]=>
  string(644) "
“This CHMP recommendation marks a breakthrough in the treatment of triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need,” said Sandra Horning, MD, 
&#nl
The post CHMP recommends EU approval of Roche’s Tecentriq plus Abraxane for metastatic TNBC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(644) "
“This CHMP recommendation marks a breakthrough in the treatment of triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need,” said Sandra Horning, MD, 
&#nl
The post CHMP recommends EU approval of Roche’s Tecentriq plus Abraxane for metastatic TNBC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/chmp-recommends-eu-approval-of-roches-tecentriq-plus-abraxane-for-metastatic-tnbc/"
  ["blog_url"]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/chmp-recommends-eu-approval-of-roches-tecentriq-plus-abraxane-for-metastatic-tnbc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3334"
  ["article_id"]=>
  string(4) "3334"
  [1]=>
  string(59) "Pfizer gets FDA nod for Avastin’s biosimilar Zirabev"
  ["article_title"]=>
  string(59) "Pfizer gets FDA nod for Avastin’s biosimilar Zirabev"
  [2]=>
  string(150) "Pfizer said that Zirabev has been approved to treat five types of cancer, including metastatic colorectal cancer; unresectable, locally advanced, recu"
  ["short_description"]=>
  string(150) "Pfizer said that Zirabev has been approved to treat five types of cancer, including metastatic colorectal cancer; unresectable, locally advanced, recu"
  [3]=>
  string(574) "
Pfizer said that Zirabev has been approved to treat five types of cancer, including metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer 
&#nl
The post Pfizer gets FDA nod for Avastin’s biosimilar Zirabev appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(574) "
Pfizer said that Zirabev has been approved to treat five types of cancer, including metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer 
&#nl
The post Pfizer gets FDA nod for Avastin’s biosimilar Zirabev appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(86) "https://www.pharmaceutical-business-review.com/news/pfizer-avastin-biosimilar-zirabev/"
  ["blog_url"]=>
  string(86) "https://www.pharmaceutical-business-review.com/news/pfizer-avastin-biosimilar-zirabev/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3335"
  ["article_id"]=>
  string(4) "3335"
  [1]=>
  string(88) "Xeris doses first patient in phase 2 trial of developmental ready-to-use glucagon in PBH"
  ["article_title"]=>
  string(88) "Xeris doses first patient in phase 2 trial of developmental ready-to-use glucagon in PBH"
  [2]=>
  string(150) "Post-bariatric hypoglycemia (PBH) is a complication of bariatric surgery thought to be related to excessive insulin secretion in response to a meal. P"
  ["short_description"]=>
  string(150) "Post-bariatric hypoglycemia (PBH) is a complication of bariatric surgery thought to be related to excessive insulin secretion in response to a meal. P"
  [3]=>
  string(624) "
Post-bariatric hypoglycemia (PBH) is a complication of bariatric surgery thought to be related to excessive insulin secretion in response to a meal. PBH can begin to occur one 
&#nl
The post Xeris doses first patient in phase 2 trial of developmental ready-to-use glucagon in PBH appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(624) "
Post-bariatric hypoglycemia (PBH) is a complication of bariatric surgery thought to be related to excessive insulin secretion in response to a meal. PBH can begin to occur one 
&#nl
The post Xeris doses first patient in phase 2 trial of developmental ready-to-use glucagon in PBH appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(141) "https://www.pharmaceutical-business-review.com/news/xeris-doses-first-patient-in-phase-2-trial-of-developmental-ready-to-use-glucagon-in-pbh/"
  ["blog_url"]=>
  string(141) "https://www.pharmaceutical-business-review.com/news/xeris-doses-first-patient-in-phase-2-trial-of-developmental-ready-to-use-glucagon-in-pbh/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3336"
  ["article_id"]=>
  string(4) "3336"
  [1]=>
  string(97) "Lung cancer drug Imfinzi improves overall survival at interim analysis in phase III CASPIAN trial"
  ["article_title"]=>
  string(97) "Lung cancer drug Imfinzi improves overall survival at interim analysis in phase III CASPIAN trial"
  [2]=>
  string(152) "A planned interim analysis conducted by an Independent Data Monitoring Committee concluded that the trial has met its primary endpoint by showing a s"
  ["short_description"]=>
  string(152) "A planned interim analysis conducted by an Independent Data Monitoring Committee concluded that the trial has met its primary endpoint by showing a s"
  [3]=>
  string(691) "
A planned interim analysis conducted by an Independent Data Monitoring Committee concluded that the trial has met its primary endpoint by showing a statistically-significant and clinically-meaningful improvement in OS 
&#nl
The post Lung cancer drug Imfinzi improves overall survival at interim analysis in phase III CASPIAN trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(691) "
A planned interim analysis conducted by an Independent Data Monitoring Committee concluded that the trial has met its primary endpoint by showing a statistically-significant and clinically-meaningful improvement in OS 
&#nl
The post Lung cancer drug Imfinzi improves overall survival at interim analysis in phase III CASPIAN trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(154) "https://www.pharmaceutical-business-review.com/news/lung-cancer-drug-imfinzi-improves-overall-survival-at-interim-analysis-in-the-phase-iii-caspian-trial/"
  ["blog_url"]=>
  string(154) "https://www.pharmaceutical-business-review.com/news/lung-cancer-drug-imfinzi-improves-overall-survival-at-interim-analysis-in-the-phase-iii-caspian-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3337"
  ["article_id"]=>
  string(4) "3337"
  [1]=>
  string(97) "FDA approves Alexion’s Soliris to treat adults with neuromyelitis optica spectrum disorder"
  ["article_title"]=>
  string(97) "FDA approves Alexion’s Soliris to treat adults with neuromyelitis optica spectrum disorder"
  [2]=>
  string(150) "The NMOSD is a rare and severe autoimmune disease, which attacks the central nervous system without warning. Also referred as relapses, the attacks ma"
  ["short_description"]=>
  string(150) "The NMOSD is a rare and severe autoimmune disease, which attacks the central nervous system without warning. Also referred as relapses, the attacks ma"
  [3]=>
  string(567) "
The NMOSD is a rare and severe autoimmune disease, which attacks the central nervous system without warning. Also referred as relapses, the attacks may result in progressive and 
&#nl
The post FDA approves Alexion’s Soliris to treat adults with neuromyelitis optica spectrum disorder appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(567) "
The NMOSD is a rare and severe autoimmune disease, which attacks the central nervous system without warning. Also referred as relapses, the attacks may result in progressive and 
&#nl
The post FDA approves Alexion’s Soliris to treat adults with neuromyelitis optica spectrum disorder appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(74) "https://www.pharmaceutical-business-review.com/news/alexion-soliris-nmosd/"
  ["blog_url"]=>
  string(74) "https://www.pharmaceutical-business-review.com/news/alexion-soliris-nmosd/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3338"
  ["article_id"]=>
  string(4) "3338"
  [1]=>
  string(76) "Acceleron completes target enrollment in phase 2 trial of Sotatercept in PAH"
  ["article_title"]=>
  string(76) "Acceleron completes target enrollment in phase 2 trial of Sotatercept in PAH"
  [2]=>
  string(164) "The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment over the pas"
  ["short_description"]=>
  string(164) "The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment over the pas"
  [3]=>
  string(623) "
The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment over the past 12 months, which underscores the 
&#nl
The post Acceleron completes target enrollment in phase 2 trial of Sotatercept in PAH appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(623) "
The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment over the past 12 months, which underscores the 
&#nl
The post Acceleron completes target enrollment in phase 2 trial of Sotatercept in PAH appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(129) "https://www.pharmaceutical-business-review.com/news/acceleron-completes-target-enrollment-in-phase-2-trial-of-sotatercept-in-pah/"
  ["blog_url"]=>
  string(129) "https://www.pharmaceutical-business-review.com/news/acceleron-completes-target-enrollment-in-phase-2-trial-of-sotatercept-in-pah/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3339"
  ["article_id"]=>
  string(4) "3339"
  [1]=>
  string(81) "FDA grants fast track designation to empagliflozin to treat chronic heart failure"
  ["article_title"]=>
  string(81) "FDA grants fast track designation to empagliflozin to treat chronic heart failure"
  [2]=>
  string(150) "The Fast Track designation facilitates the development of new therapies that fill an unmet medical need for serious conditions in an effort to expedit"
  ["short_description"]=>
  string(150) "The Fast Track designation facilitates the development of new therapies that fill an unmet medical need for serious conditions in an effort to expedit"
  [3]=>
  string(610) "
The Fast Track designation facilitates the development of new therapies that fill an unmet medical need for serious conditions in an effort to expedite the availability of new 
&#nl
The post FDA grants fast track designation to empagliflozin to treat chronic heart failure appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(610) "
The Fast Track designation facilitates the development of new therapies that fill an unmet medical need for serious conditions in an effort to expedite the availability of new 
&#nl
The post FDA grants fast track designation to empagliflozin to treat chronic heart failure appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/fda-grants-fast-track-designation-to-empagliflozin-to-treat-chronic-heart-failure/"
  ["blog_url"]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/fda-grants-fast-track-designation-to-empagliflozin-to-treat-chronic-heart-failure/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3340"
  ["article_id"]=>
  string(4) "3340"
  [1]=>
  string(92) "Regeneron, Sanofi get FDA nod for Dupixent to treat chronic rhinosinusitis with nasal polyps"
  ["article_title"]=>
  string(92) "Regeneron, Sanofi get FDA nod for Dupixent to treat chronic rhinosinusitis with nasal polyps"
  [2]=>
  string(150) "The approval allows the drug firms to use Dupixent with other medicines for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in a"
  ["short_description"]=>
  string(150) "The approval allows the drug firms to use Dupixent with other medicines for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in a"
  [3]=>
  string(572) "
The approval allows the drug firms to use Dupixent with other medicines for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not 
&#nl
The post Regeneron, Sanofi get FDA nod for Dupixent to treat chronic rhinosinusitis with nasal polyps appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(572) "
The approval allows the drug firms to use Dupixent with other medicines for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not 
&#nl
The post Regeneron, Sanofi get FDA nod for Dupixent to treat chronic rhinosinusitis with nasal polyps appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/regeneron-sanofi-dupixent-nasal/"
  ["blog_url"]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/regeneron-sanofi-dupixent-nasal/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3341"
  ["article_id"]=>
  string(4) "3341"
  [1]=>
  string(88) "Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation"
  ["article_title"]=>
  string(88) "Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation"
  [2]=>
  string(150) "IMB-115 is an internally discovered compound with a novel mechanism of action in clinical development for the treatment of insomnia disorders, includi"
  ["short_description"]=>
  string(150) "IMB-115 is an internally discovered compound with a novel mechanism of action in clinical development for the treatment of insomnia disorders, includi"
  [3]=>
  string(652) "
IMB-115 is an internally discovered compound with a novel mechanism of action in clinical development for the treatment of insomnia disorders, including insomnia associated with alcohol cessation (IAAC). 
&#nl
The post Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(652) "
IMB-115 is an internally discovered compound with a novel mechanism of action in clinical development for the treatment of insomnia disorders, including insomnia associated with alcohol cessation (IAAC). 
&#nl
The post Imbrium initiates phase 2 study of IMB-115 in insomnia associated with alcohol cessation appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(141) "https://www.pharmaceutical-business-review.com/news/imbrium-initiates-phase-2-study-of-imb-115-in-insomnia-associated-with-alcohol-cessation/"
  ["blog_url"]=>
  string(141) "https://www.pharmaceutical-business-review.com/news/imbrium-initiates-phase-2-study-of-imb-115-in-insomnia-associated-with-alcohol-cessation/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:48:53"
  ["create_at"]=>
  string(19) "2019-07-02 11:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "3433"
  ["article_id"]=>
  string(4) "3433"
  [1]=>
  string(33) "2nd Annual Biotechnology Congress"
  ["article_title"]=>
  string(33) "2nd Annual Biotechnology Congress"
  [2]=>
  string(150) "Conference Series LLC Ltd invites you for the 2nd Annual Biotechnology Congress which is going to be held in July 31-Aug 1, 2019 Chicago, USA. This is"
  ["short_description"]=>
  string(150) "Conference Series LLC Ltd invites you for the 2nd Annual Biotechnology Congress which is going to be held in July 31-Aug 1, 2019 Chicago, USA. This is"
  [3]=>
  string(516) "Conference Series LLC Ltd invites you for the 2nd Annual Biotechnology Congress which is going to be held in July 31-Aug 1, 2019 Chicago, USA. This is a fabulous open door for the representatives from Universities, Institutes, and industries to communicate on one platform and to discuss the diverse uses of Biotechnology.&#nl&#nlAnnual Biotechnology Congress aims to bring together the Professors, Researchers, scientists, business giants, and technocrats to provide an international forum for the disse…"
  ["description"]=>
  string(516) "Conference Series LLC Ltd invites you for the 2nd Annual Biotechnology Congress which is going to be held in July 31-Aug 1, 2019 Chicago, USA. This is a fabulous open door for the representatives from Universities, Institutes, and industries to communicate on one platform and to discuss the diverse uses of Biotechnology.&#nl&#nlAnnual Biotechnology Congress aims to bring together the Professors, Researchers, scientists, business giants, and technocrats to provide an international forum for the disse…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(82) "
https://www.pharmiweb.com/event/2nd-annual-biotechnology-congress                "
  ["blog_url"]=>
  string(82) "
https://www.pharmiweb.com/event/2nd-annual-biotechnology-congress                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-07-02 11:49:31"
  ["create_at"]=>
  string(19) "2019-07-02 11:49:31"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}